RBC Capital Initiates a Buy Rating on Hookipa Pharma (HOOK)

In a report released yesterday, Brian Abrahams from RBC Capital initiated coverage with a Buy rating on Hookipa Pharma (HOOK – Research Report) and a price target of $5.00. The company’s shares closed yesterday at $0.80.

According to TipRanks, Abrahams is a 4-star analyst with an average return of 7.3% and a 48.39% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as SAGE Therapeutics, Biogen, and Incyte.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Hookipa Pharma with a $5.00 average price target, representing a 525.00% upside. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $5.00 price target.

The company has a one-year high of $2.05 and a one-year low of $0.41. Currently, Hookipa Pharma has an average volume of 805.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Hookipa Pharma (HOOK) Company Description:

HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary its arenavirus platform that is designed to reprogram the body’s immune system. Its product include VaxWace, a replication-deficient viral vector; and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.